Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Renal Cell Carcinoma
•
Urology
•
Urologic Oncology
•
Survivorship
What is your approach to surveillance in patients with no evidence of disease after treatment of oligometastatic renal cell carcinoma?
How long do you generally continue clinical and/or imaging surveillance?
Related Questions
For a patient post-prostatectomy with a high PSA (>1), a negative MRI pelvis, and a negative PSMA PET scan, do you pursue any other imaging?
How do you decide between internal versus external decompression of malignant obstruction of the ureter (MUO)?
What chemotherapy regimen do you use for de novo metastatic squamous cell carcinoma of penile urethra?
How would you approach a patient with metastatic renal cell carcinoma who developed a STEMI while on TKI (Lenvatinib) and immunotherapy combination?
In which patients are referring for focal gland therapy for localized prostate cancer?
What adjuvant therapy, if any, is best for mucinous tubular and spindle cell carcinoma of the kidney?
How do you reconcile the lack of OS benefit in the CLEAR trial comparing Lenvatinib + Pembrolizumab to Sunitinib, to the very impressive ORR and mPFS benefit seen?
Do you add ADT to RT for a patient with intermediate-risk prostate cancer with discordant Decipher and ArteraAI results?
What are your top takeaways from ASCO GU 2025?
How do you manage hypoxia induced by belzutifan?